Douglas J. Gentilcore - 17 Jan 2025 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
SVP, Danyelza Bus. Unit Head
Signature
/s/ John LaRocca, Attorney-in-Fact
Issuer symbol
YMAB
Transactions as of
17 Jan 2025
Transactions value $
$0
Form type
4
Filing time
22 Jan 2025, 19:03:02 UTC
Previous filing
17 Jan 2025
Next filing
18 Sep 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Award $0 +142,600 $0 142,600 17 Jan 2025 Common Stock 142,600 $6.16 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.
F2 The stock options shall vest and become exercisable as to 25% of the shares subject to the option on January 17, 2026, and thereafter vest and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.